The KCTD20 Knockout HT29 Polyclonal Cells provide a loss-of-function model for investigating KCTD20 gene function in a colorectal adenocarcinoma background. This product consists of a polyclonal population of HT29 cells that have undergone CRISPR/Cas9-mediated disruption of the KCTD20 locus. The polyclonal format maintains genetic heterogeneity, making it well-suited for experiments where clonal isolation is not required. Researchers can utilize this model to study the consequences of KCTD20 ablation on cellular signaling and tumorigenic properties without the confounding effects of clonal variability.
The HT29 host cell line was derived from a 44-year-old female with colorectal adenocarcinoma and displays an adherent, epithelial morphology. HT29 cells are a widely employed intestinal epithelial model with both absorptive and mucin-secreting capabilities, facilitating colorectal cancer research. These cells exhibit aberrant WNT/??-catenin signaling, a hallmark of colorectal tumorigenesis, providing a clinically relevant genetic context for examining the role of KCTD20 in oncogenic pathways.
KCTD20 functions as a substrate adaptor for the Cullin3-RING E3 ubiquitin ligase complex, promoting target protein ubiquitination and proteasomal degradation. It is transcriptionally regulated by ??-catenin/TCF4 and MYC, downstream of WNT signaling. Although direct substrates are unknown, KCTD20 likely modulates Hedgehog and WNT pathways, with candidate targets such as GLI1 or ??-catenin. The KCTD20 interactome includes CUL3, RBX1, and ubiquitin-conjugating enzymes, and it connects to pathways involving SHH/PTCH1/SMO/GLI1 and WNT3A/FZD/??-catenin/TCF/LEF.
In HT29 cells, KCTD20 knockout impairs substrate ubiquitination, stabilizing proteins normally degraded. Given constitutive WNT activation, loss of KCTD20 may further enhance ??-catenin/TCF transcription and disrupt Hedgehog signaling, potentially driving proliferation and survival phenotypes linked to adenoma-carcinoma progression. This model enables dissection of ubiquitin-mediated control of oncogenic pathways in colorectal cancer.
Applications include functional genomics of the Cullin3-RING E3 pathway, Hedgehog-WNT crosstalk studies, and drug target validation. Assays such as Western blotting, ubiquitination and proteasome activity measurements, RNA-seq, and RT-qPCR can detect molecular changes. WNT/??-catenin reporter assays and immunofluorescence monitor pathway activity. Standard proliferation, apoptosis, and migration/invasion assays characterize phenotypic outcomes. For further technical details, please contact Ascent Research.
